Neuroprotectants offer hope to glaucoma sufferers

Article

Erythropoietin (EPO), ciliary neurotrophic factor (CNTF), and wolfberry seem to provide neuroprotection of retinal ganglion cells in a rat model of ocular hypertension.

Erythropoietin (EPO), ciliary neurotrophic factor (CNTF), and wolfberry seem to provide neuroprotection of retinal ganglion cells in a rat model of ocular hypertension, according to Kwoh-fai So, PhD, chairman of the Department of Anatomy, University of Hong Kong.

Dr So and colleagues created a rat model of ocular hypertension in which the retinal ganglion cells were affected, and tested EPO, CNTF, and wolfberry, a Chinese herb, in three separate experiments. All three seemed to be neuroprotective of the retinal ganglion cells.

“Endogenous EPO seems to have a recovery mechanism after retinal injury and the retinal ganglion cells might be rescued by endogenous EPO,” Dr So said. “CNTF enhanced regeneration and is an effective neurotrophic factor in protecting retinal ganglion cells in the rat model.

“Wolfberry is very interesting to us because it improves visual acuity, benefits the liver and kidney, and adjusts the body’s immunity and also was protective of retinal ganglion cells in this rat model,” Dr So said. “Wolfberry might be a useful treatment because it is a safe herbal medicine that has been used for a long time.”

Investigators are also studying the effect of wolfberry on microglia.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.